Targeting gd T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application

• Autor(a) principal: Gomes, Anita Q.
• Data de Publicação: 2010
• Outros Autores: Martins, Duarte S., Silva-Santos, Bruno
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.21/12195
• topic: Humans; Immunotherapy, Adoptive; Lymphocyte activation; Neoplasms; Receptors, Antigen; T-Cell; Gamma-delta; T-Lymphocyte subsets

Abundant interferon-γ secretion, potent cytotoxicity, and major histocompatibility complex-independent targeting of a large spectrum of tumors make γδ T cells attractive mediators of cancer immunotherapy. However, a better understanding of the molecular mechanisms involved in tumor cell recognition and γδ T-cell activation is required to improve the limited success of γδ T-cell-mediated treatments. Here, we review key advances in basic knowledge made over the past 3 years and summarize the results of γδ T-cell-based clinical trials concluded to date. We also highlight new research directions on the basis of the modulation of receptors that control the function of γδ T cells.